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MaPulmonary hypertension (PH) is a classic pathophysiological consequence of left-sided valvular heart disease (VHD).
However, as opposed to other forms of PH, there are relatively few published data on the prevalence, impact on
outcome, and management of PH with VHD. The objective of this paper is to present a systematic review of PH in patients
with VHD. PH is found in 15% to 60% of patients with VHD and is more frequent among symptomatic patients. PH is
associated with higher risk of cardiac events under conservative management, during valve replacement or repair pro-
cedures, and even following successful corrective procedures. In addition to its usefulness in assessing the presence and
severity of VHD, Doppler echocardiography is a key tool in diagnosis of PH and assessment of its repercussion on right
ventricular function. Assessment of pulmonary arterial pressure during exercise stress echocardiography may provide
additional prognostic information beyond resting evaluation. Cardiac magnetic resonance is also useful for assessing right
ventricular geometry and function, which provide additional prognostic information in patients with VHD and PH.
(J Am Coll Cardiol Img 2015;8:83–99) © 2015 by the American College of Cardiology Foundation.P ulmonary hypertension (PH) related to leftheart disease represents group 2 of the newclinical classiﬁcation of PH (1), and subgroup
2.3 is speciﬁcally dedicated to valvular heart disease
(VHD). VHD is a frequent etiology of PH, which may
result from multiple mechanisms such as an increase
in pulmonary vascular resistance, pulmonary blood
ﬂow, or pulmonary venous pressure. The chronic
rise in pulmonary arterial pressure (PAP) often leads
to right ventricular (RV) pressure overload and subse-
quent RV failure. When present, PH is a marker of
poor outcome in VHD. Assessment of the presence
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In this paper, we review all relevant studies
reporting mechanism, prevalence, and impact on
outcomes of PH in patients with left-sided VHD. The
ﬁnal selection of discussed studies was based on the
authors’ consensus regarding robustness of data,
sample size, and quality of methodology.
DEFINITION
Deﬁnitive diagnosis of PH related to VHD is based on
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ABBR EV I A T I ON S
AND ACRONYMS
AR = aortic regurgitation
AS = aortic stenosis
AVR = aortic valve
replacement
LA = left atrial/atrium
LV = left ventricular/ventricle
MR = mitral regurgitation
MS = mitral stenosis
PAP = pulmonary arterial
pressure
PCWP = pulmonary capillary
wedge pressure
PH = pulmonary hypertension
RA = right atrial
RV = right ventricular/ventricle
TR = tricuspid regurgitation
VHD = valvular heart disea
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84together with an abnormally high pulmonary
capillary wedge pressure (PCWP) >15 mm Hg
or left ventricular (LV) end-diastolic pressure
>18 mm Hg in the context of signiﬁcant
VHD. When pulmonary venous congestion is
the main determinant of PH, PH is named
isolated post-capillary PH or pulmonary
venous hypertension. In this case, the
transpulmonary pressure gradient is <7 to
10 mm Hg and the pulmonary vascular
resistance is <1.5 Wood Units. In the more
advanced stage of the disease, combined
post-capillary and pre-capillary PH can be
observed (PCWP >15 mm Hg and trans-
pulmonary pressure gradient $7 to 10 mm Hg
or pulmonary vascular resistance >1.5 Wood
Units) (3). This form of PH is considered “out
of proportion” to the LV ﬁlling pressure
and results from a mixed pathophysiology
(passive venous transmission, reversiblepulmonary arterial vasoconstriction, ﬁxed pulmonary
vascular remodeling).
PATHOPHYSIOLOGY
An increase in LV ﬁlling pressure and left atrial (LA)
pressure leads to a passive rise in backward pres-
sure of the pulmonary vein (Figure 1). Persistently
elevated pulmonary venous pressure can favor frag-
mentation of the structure and result in “alveolar-
capillary stress failure,” accompanied by capillary
leakage and acute alveolar edema. This acute phase is
completely reversible, but long-term persistence of
high pulmonary venous pressure may induce some
degree of irreversible remodeling of the alveolar-
capillary membrane, with excessive deposition of
type IV collagen. In addition, chronic elevated pul-
monary venous pressure progressively and passively
increases PAP and concomitantly produces patho-
logical changes in pulmonary veins (Figure 1) and
arteries, leading to increased pulmonary vascular
resistance (3). The pathophysiology of PH in VHD
thus involves progressive structural alteration of the
pulmonary vascular bed mediated by the potent
vasoconstrictor endothelin-1 (4). An increase in
pulmonary-arterial vasoconstriction and systolic PAP
results into RV dilation and hypertrophy. The RV
failure is associated with tricuspid annulus dilation
and an increase in tricuspid regurgitation severity,
which further acerbates RV dysfunction. At the
decompensated phase, systolic PAP can decrease
despite the increase in pulmonary vascular resis-
tance, due to the fall in RV stroke volume related to
advanced RV failure.
seAfter treatment, the reversibility of PH depends on
the type, severity, and chronicity of VHD, as well as
the underlying pathophysiological adaptations. For
instance, in mitral stenosis (MS), a rapid decrease in
PAP is observed after relief of the stenosis, whereas a
longer time could be required in other VHDs, espe-
cially when PH is linked to volume overload, as in
mitral regurgitation (MR).
DIAGNOSTIC WORK-UP
Distinctive clinical signs and symptoms of left-sided
VHD PH are orthopnea and paroxysmal nocturnal
dyspnea, which are generally not features of other
types of PH (5). However, patients can remain
asymptomatic for a long time, which often delays the
diagnosis. Signs of RV failure, such as peripheral
edema, ascites, and syncope, are frequently observed
at an advanced stage of the disease. Clinical tests
frequently reveal ﬁndings suggestive of left-sided
VHD PH: presence of signiﬁcant VHD; pulmonary
vascular congestion, pleural effusion, or pulmonary
edema on chest x-ray or computed tomography; and
LV/LA hypertrophy on electrocardiogram.
Although current European guidelines state that
Doppler echocardiography does not measure PAP but
gives only an estimate of it and that right heart
catheterization is mandatory for the conﬁrmation of a
PH diagnosis, echocardiography remains key for the
differential diagnosis and evaluation of consequences
of PH and has a central role in the assessment of VHD.
Furthermore, in this speciﬁc clinical setting and in
the likely diagnosis of PH using echocardiography
(Table 1), the requirement of invasive measurement of
PAP could be debated. Nuclear imaging has little use
in this setting except to rule out ischemic heart dis-
ease, detect viable myocardium, and evaluate ven-
tricular function. Similar information can be obtained
with cardiac magnetic resonance, the main role of
which is to evaluate the consequences/causes of VHD.
In some cases, invasive hemodynamic evaluation
with right heart catheterization is required to conﬁrm
the diagnosis because echocardiography often un-
derestimates the systolic PAP and does not provide an
accurate assessment of PCWP (or mean PAP).
RESTING ECHOCARDIOGRAPHY. In patients with
conﬁrmed or suspected PH, echocardiography is
helpful for: 1) detection of increased right chamber
pressure; 2) evaluation of RV changes as a conse-
quence of increased afterload; 3) assessment of LV size
and function; and 4) measurement of systolic PAP.
PH can be reasonably excluded when the following
parameters are within the normal range or absent
(Table 1, Figure 2) (6–8): LV and RV size and function
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FIGURE 1 Mechanisms and Pathophysiology of PH in Patients With VHD
ET1 ¼ endothelin-1; LA ¼ left atrium; LV ¼ left ventricle; LVED ¼ left ventricular end-diastolic; PVR ¼ pulmonary vascular resistance; PA ¼ pulmonary arterial;
PH ¼ pulmonary hypertension; RV ¼ right ventricle; TNF ¼ tumor necrosis factor; VHD ¼ valvular heart disease.
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TABLE 1 Echocardiographic Features Diagnosing PH According to TR Peak Velocity and Complementary Supportive Signs of PH
sPAP Assessment Supportive Echocardiographic Signs
Presence of PH
Peak TR
Velocity
Estimated
sPAP Inferior VC RV vs. LV Septal Wall Pulmonary AT
#2.8 m/s #36 mm Hg Normal (#2 cm)
Normal inspiratory
collapse (>>50%)
RV size < LV size Normal >100 ms Unlikely (Class I, LOE: B)
#2.8 m/s #36 mm Hg Discordant ﬁndings Low probability*
#2.8 m/s #36 mm Hg Dilated (>2 cm)
Inspiratory collapse <50%
RV size $ LV size Bowing; motion
abnormalities
<100 ms Possible (Class IIa, LOE: C)
2.9–3.4 m/s 37–50 mm Hg Normal (#2 cm)
Normal inspiratory
collapse (>>50%)
RV size < LV size Normal >100 ms Possible (Class IIa, LOE: C)
2.9–3.4 m/s 37–50 mm Hg Dilated (>2 cm)
Inspiratory collapse <50%
RV size $ LV size Bowing; motion
abnormalities
<100 ms High probability*
>3.4 m/s >50 mm Hg Likely (Class I, LOE: B)
*Indicates the lack of such a level of probabilities reported in the current guidelines (1). Reproduced with permission of the European Respiratory Society (7).
AT ¼ acceleration time; LOE ¼ Level of Evidence; LV ¼ left ventricle; PH ¼ pulmonary hypertension; RV ¼ right ventricle; sPAP ¼ systolic pulmonary arterial pressure;
TR ¼ tricuspid regurgitation; VC ¼ vena cava.
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86(including wall motion), intracardiac shunt, pericar-
dial effusion, tricuspid regurgitation (TR) jet velocity
(i.e.,<2.8m/s), inferior vena cava diameter (i.e.,<2.1 cm),
and pulmonary acceleration time (i.e., >100 ms).
Nevertheless, if at least 1 of these parameters is found
to be abnormal, or if several of these parameters
are close to normal reference values, current expert
consensus recommends performing a more advanced
echocardiographic examination, including more
quantitative assessment of cardiac hemodynamics and
chamber sizes and function (Figure 3).
In patients with VHD, although there are overt
limitations in some patients pertaining to the inability
to detect TR and accurately measure its peak velocity,
the most commonly used technique to estimate sys-
tolic PAP remains the direct measurement of peak TR
jet velocity, which, according to the simpliﬁed Ber-
noulli equation (peak gradient ¼ 4v2), provides the
derived RV systolic pressure. The systolic PAP is the
sum of RV þ right atrial (RA) pressures. The RA pres-
sure may be derived from the inferior vena cava
diameter and its changes during the respiratory cycle
(6,7). Based upon the measurement of peak TR jet
velocity and some basic echocardiographic features of
PH, the following algorithm has been suggested to
identify PH (Table 1): for a given RA pressure assumed
at 5 mm Hg, systolic PAP #36 mm Hg ¼ PH unlikely;
systolic PAP >50 mm Hg ¼ likely (Class I, Level of
Evidence: B); and systolic PAP #36 mm Hg but with
obvious echocardiographic signs of PH or systolic PAP
37 to 50mmHg¼ possible (Class IIa, Level of Evidence:
C). In practice, it is reasonable to consider a systolic
PAP $36 mm Hg (TR $2.8 m/s þ RA pressure) as an
appropriate threshold for PH. This should be lower in
elderly patients and obese patients (6) because restingphysiological range of TR velocity–derived systolic
PAP highly depends on these conditions. Of note, the
estimation of systolic PAP using TR jet velocity is not
appropriate for very severe/massive TR.
Despite all overt limitations, measurement of sys-
tolic PAP using Doppler echocardiography remains
highly reproducible and, more importantly, closely
associated with outcome.
EXERCISE STRESS ECHOCARDIOGRAPHY. During
exercise and secondary to the increase in oxygen
demand, cardiac output increases more than 3- to 4-
fold. The pulmonary vascular bed is a low-
resistance high-compliance system. To accommo-
date the increase in ﬂow and volume, the pulmonary
vascular bed has the ability to recruit and distend
pulmonary arterial vessels, leading to a drop in pul-
monary vascular resistance and a moderate increase
in PAP in response to an important increase in cardiac
output (9). The magnitude of increase in systolic PAP
during exercise depends on the ability to successfully
recruit the pulmonary vasculature to accommodate
increased blood ﬂow with exercise, contribution of
the reduction in cross-sectional area of the pulmo-
nary circulation, reduction in pulmonary vascular
compliance, increase in LA pressure in relation to the
severity of diastolic dysfunction and VHD severity,
and RV function adaptation. In VHD, systolic PAP at
exercise does not simply reﬂect the increase in car-
diac output, but development of exercise PH may be
seen as an accurate marker of early, subclinical, and
silent consequences of the disease. Indeed, exercise
PH is frequently observed in asymptomatic patients
with advanced age, more severe VHD, elevated
resting and exercise LV ﬁlling pressures, and
enlarged LA. Although asymptomatic at rest, patients
FIGURE 2 Basic Echocardiographic Assessment of PH
The assessment of PH includes measurements of tricuspid regurgitation (TR) peak velocity (A), pulmonary acceleration time (AcT) (B), and
inferior vena cava diameter (C). RA ¼ right atrium; other abbreviation as in Figure 1.
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87with VHD and exercise PH often develop exertion
dyspnea and became rapidly symptomatic during
follow-up. Conversely, exercise systolic PAP provides
useful information on individual patient outcome
(10,11). Nonetheless, elevated exercise systolic PAP
(i.e., >60 mm Hg) should be cautiously interpreted in
regard to patient age, exercise workload, and cardiac
output. Rather than peak exercise systolic PAP, the
kinetic of exercise-induced changes in PAP,
throughout the exercise test, seems to provide the
most valuable information regarding pulmonary
vascular function adaptation (12). Indeed, whereas
progressive increase in PAP during exercise with end-
stage development of exercise PH should not neces-
sarily be labeled as abnormal, early and steep increases
in PAP of >60 mm Hg at the ﬁrst stages of exercise
followed by a plateau may diagnose advanced disease
(13). The former may be seen as a “normal” adaptation
to exercise because healthy subjects may regularly
exceed 60 mm Hg during exercise (14). The latter,
however, is more frequently associated with exerciseRV dysfunction and occurrence of symptoms during
the test.
SPECIFIC ISSUES. RV assessment. Owing to its acces-
sibility, rapidity of acquisition, and cost, echocardi-
ography is the ﬁrst-line imaging modality to evaluate
the RV. Nevertheless, cardiac magnetic resonance is
now considered the gold standard for RV assessment.
The basic evaluation of RV geometry should include
the measurement of RV cavity dimensions and vol-
umes and RV wall thickness, as well as the identiﬁ-
cation of wall morphological abnormalities. The
simplest method used in clinical practice to screen for
RV dilation is the measurement of RV end-diastolic
and end-systolic areas and linear dimensions (RV
basal and mid-cavity diameters and RV outﬂow tract
proximal and distal diameters) using single echocar-
diographic planes (Table 2) (15). Measurement of RV
wall thickness may help to identify hypertrophy. The
normal RV has a wall thickness of <5 mm, as measured
from the subcostal or parasternal long-axis views or
corresponding cardiac magnetic resonance slices.
FIGURE 3 Advanced Echocardiographic Assessment of RV Function
Healthy patient (A) and patient with pulmonary hypertension secondary to left-sided mitral valve disease (B). CMR ¼ cardiac magnetic
resonance; EDV ¼ end-diastolic volume; ESV ¼ end-systolic volume; IVCT ¼ isovolumic contraction time; IVRT ¼ isovolumic relaxation time;
MPI ¼ myocardial performance index; PW ¼ pulsed wave; RVEF ¼ right ventricular ejection fraction; TAPSE ¼ tricuspid annular plane systolic
excursion; TDI ¼ tissue Doppler imaging; other abbreviation as in Figure 1.
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TABLE 2 Summary of Doppler Echocardiographic Parameters and Criteria Used for
the Identiﬁcation of RV Dilation and Dysfunction
Threshold for
Abnormal Value Limitations
RV basal diameter >41 mm Dependent on probe rotation
RV mid-cavity diameter >35 mm Dependent on probe rotation;
no validated reference point
RV base-to-apex diameter >86 mm Identiﬁcation of the apical point;
dependent on probe rotation
RV free wall thickness
(subcostal or PSLA view)
>5 mm Endocardial border delineation
(trabeculations)
LV eccentricity index >1
Fractional area change <35% Endocardial border delineation
TAPSE <17 mm Dependent on alignment with
RV free wall; less accurate in
case of free TR
Peak S0-wave velocity of
the tricuspid annulus
<9.5 cm/s Dependent on alignment with
RV free wall; less accurate in
case of free TR
Myocardial performance
index
PW Doppler <0.43,
PW TDI <0.54 Angle dependent
RV free wall longitudinal
strain
<20% Dependent on image quality
(angle dependency of TDI)
3D echocardiography
RV ejection fraction <44% Dependent on image quality;
endocardial border delineationRV end-diastolic volume >87 (M) or 74 (F) ml/m2
RV end-systolic volume >44 (M) or 36 (F) ml/m2
Reference ranges are derived from the Recommendations on Chamber Quantiﬁcation published jointly by the
American Society of Echocardiography and the European Association of Cardiovascular Imaging (8).
3D ¼ 3-dimensional; F ¼ female threshold; M ¼ male threshold; PSLA ¼ parasternal long axis; PW ¼ pulsed
wave; TAPSE ¼ tricuspid annular plane systolic excursion; TDI ¼ tissue Doppler imaging; TR ¼ tricuspid
regurgitation; other abbreviations as in Table 1.
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89The LV eccentricity index (i.e., the ratio of the LV
anteroposterior to septolateral diameters in short-axis
view), measured just slightly above the papillary
muscles, is one of the parameters that can be used to
detect changes in RV shape, providing quantitative
assessment of septal ﬂattening. In normal states, the
LV eccentricity index is 1, both in systole and diastole.
By echocardiography, RV function can be evaluated
using multiple parameters, among which the frac-
tional area change, tricuspid annular systolic plane,
and peak systolic tricuspid annular velocity are the
most common (Table 2, Figures 3A and 3B). Three-
dimensional (3D) echocardiography–derived RV ejec-
tion fraction is a global measure of RV systolic
performance, which incorporates the contributions of
both radial and longitudinal ﬁbers, as well as the
outﬂow tract. Accurate volume analysis independent
of RV size and shape, without foreshortened views
and geometric assumptions, ensures the superiority
of real-time 3D echocardiography for RV size and
function assessment over the conventional echocar-
diographic methods. Good correlation between real-
time 3D and cardiac magnetic resonance imaging for
calculating RV volumes and ejection fraction has been
reported, and RV volumes calculated from 3D echo-
cardiography have shown signiﬁcantly better agree-
ment and lower intraobserver and interobserver
variability than 2D echocardiography. Real-time 3D
echocardiography quantitation of RV end-diastolic
volume was recently demonstrated to be feasible
and superior to 2D in the subset of patients with pri-
mary PH. The capability to complement RV assess-
ment with geometric data on tricuspid valve tenting in
TR secondary to PH conﬁrms the unique value of real-
time 3D echocardiography to comprehensively eval-
uate patients with PH (16). Nevertheless, the inability
to cooperate for breath-holding, arrhythmias, the
larger footprint and size of matrix-array transducers,
dependence on optimal acoustic quality, and need for
speciﬁc training are among the drawbacks of 3D
echocardiography. Currently, limited data are avail-
able regarding normal reference values for RV volumes
and ejection fraction using real-time 3D echocardiog-
raphy. In addition, 3D echocardiography tends to
slightly underestimate RV volumes compared with
cardiac magnetic resonance, despite similar RV ejec-
tion fraction estimation between the 2 methods (17).
For adequate measurement of RV volumes with
cardiac magnetic resonance, the following features
should be taken into account: correct identiﬁcation of
the tricuspid and pulmonary valve planes, correct
delineation of endocardial borders in the heavily
trabeculated apical segments, and correct deﬁnition
of RV apex.TR assessment. Secondary TR is common in patients
with left-sided VHD. It is characterized by structurally
normal leaﬂets and is due to annular dilation and/or
leaﬂet tethering (18). TR severity assessment requires
the integration of multiple qualitative and quantita-
tive parameters often derived from 2D/3D trans-
thoracic Doppler echocardiography. Large coaptation
defects or tricuspid valve ﬂails indicate severe TR. A
peak tricuspid E-wave velocity >1 m/s by pulsed-
wave Doppler in the absence of tricuspid stenosis or
systolic hepatic ﬂow reversal is also suggestive of
severe TR. A vena contracta width of >7 mm and/or a
proximal isovelocity surface area radius of >9 mm at a
Nyquist limit of 28 cm/s (effective regurgitant oriﬁce
area of >40 mm2 and regurgitant volume greater
>45 ml) indicate severe TR. Conventionally, a sig-
niﬁcant tricuspid annular dilation by 2D echocar-
diography is deﬁned by a diastolic diameter in a
4-chamber view of $40 mm or >21 mm/m2. Signiﬁ-
cant leaﬂet tethering is suggested by a coaptation
distance of >8 mm in a 4-chamber view in mid-
systole. Three-dimensional echocardiography can
overcome the common limitations of 2D examina-
tions. Actually, the regurgitant oriﬁce shape, as well
as that of the tricuspid annulus, is not circular but
TABLE 3 Summary o
VHD Co
Aortic stenosis Re
Ex
Mitral stenosis Re
Ex
Aortic regurgitation Re
Ex
Primary MR Re
Ex
Secondary MR Re
Ex
*PH was deﬁned as systoli
ACC/AHA ¼ American Co
disease; other abbreviation
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90elliptical. With 3D echocardiography, the actual ge-
ometry of the ﬂow convergence and the tricuspid
annulus can be evaluated without any geometric as-
sumptions. To date, data derived from 3D echocardi-
ography are still limited. When the imaging quality is
poor, cardiac magnetic resonance can be used to
evaluate the severity of TR.
AORTIC STENOSIS
PREVALENCE. The prevalence of PH varies consid-
erably over studies (19–24), according to patient se-
lection criteria and the threshold used to deﬁne PH
(Table 3). Resting PH has been reported echocardio-
graphically in up to 15% to 30% (>19% mild: >10% to
45% moderately elevated systolic PAP 30 to 50
mm Hg; 15% to 30% severe: systolic PAP >50 mm Hg;
and 19% very severe: systolic PAP >60 mm Hg) of
patients with symptomatic aortic stenosis (AS) (22).
In a catheterization-based study (n ¼ 2,185; various
degrees of AS; unpublished data) (Figure 4), 23% of
patients had mild PH (mean PAP >25 mm Hg), 8.9%
moderate PH (mean PAP >35 mm Hg), and 4.8%
severe PH (mean PAP >45 mm Hg). Its prevalence,
however, was as low as 6% in “truly” asymptomaticf the Prevalence and Prognostic and Therapeutic Implications of Patient
ndition
Overall
prevalence of PH* Impact of PH on Outcome
AC
Patie
st 15%–30% Controversial; z2-fold increase
of 1 year in mortality after
intervention
ercise 55% z2-fold increase in risk of cardiac
event in asymptomatic patients
st >40% Event-free survival: 77% at
10 years and 41% at 15 yrs
ercise 79% Stag
st >25% Controversial
ercise
st 20%–30% and 6%–30%
in asymptomatic
patients; <20% in
asymptomatic
patients with
preserved LVEF
>2-fold increase in risk of
post-operative death
Stag
ercise z50% >3-fold increase in risk of
occurrence of symptoms
st 37%–62% z1.4-fold increase in risk of death
ercise 40% >3-fold increase of cardiac event;
>5-fold increase in risk of death;
involved in pathogenesis of
acute pulmonary edema
c PAP >50 mm Hg at rest and >60 mm Hg during exercise.
llege of Cardiology/American Heart Association; ESC ¼ European Society of Cardiology; LVE
s as in Table 1.patients (11). In this latter group, the impact of severe
AS and associated LV diastolic function (25) is
generally well counterbalanced by LA compliance
and/or pulmonary vascular compliance/resistance.
IMPACT ON OUTCOME. The most frequent features
of PH in patients with AS are impaired LV function,
concomitant MR, and increased LV end-diastolic
pressure (26). The degree of PH is mainly related to
the diastolic burden (i.e., LV end-diastolic pressure,
LA size, and compliance), whereas it is weakly
correlated with the extent of systolic dysfunction and
not to the AS severity.
When conservatively treated, moderately elevated
or worse systolic PAP is a marker of poor outcome
(26–28). Nonetheless, evidence of impaired outcome
of patients with PH receiving aortic valve replace-
ment (AVR) is weaker. Melby et al. (24) reported a
graded relationship between the levels of pre-
operative systolic PAP and reduced post-operative
survival, regardless of age, LV ejection fraction,
symptoms, diabetes, or renal failure. These results
contrasted with data from Cam et al. (27), showing
no independent impact of pre-operative mean
PAP on post-operative survival. Nevertheless, earlys With PH and VHD
Guidelines for Surgery
(Ref. #)
C/AHA
nt Class ACC/AHA ESC
— None None (20,21,24,27,84)
— None None (11)
— None Class IIa, LOE: C (36,40)
e B Mitral valve area >1.5 cm2
and pulmonary arterial
wedge pressure during
exercise >25 mm Hg:
Class IIb, LOE: C*
None (43)
— None None (45,46)
— None None
e C1 Class IIa, LOE: B Class IIa, LOE: C (48,52)
— None Class IIb, LOE: C (10,54)
— None None (51,57,59,85)
— None None (64,66,67)
F ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; VHD ¼ valvular heart
9%9.6%
14%
8.9%
FIGURE 4 Prevalence of Mild, Moderate, and Severe PH According to Left-Sided VHD
The presence and severity of PH was derived from right heart cardiac catheterization and
the measurement of mean pulmonary arterial pressure (mPAP). Mild, moderate, and severe
PH were deﬁned as mPAP >25 mm Hg, 35 mm Hg, and 45 mm Hg, respectively.
Abbreviations as in Figure 1.
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91improvement in mean PAP following surgery was
predictive of outcome.
Severe PH mainly affects in-hospital survival and
morbidity, whereas 5-year survival is affected simi-
larly by any degree of PH (24). In transcatheter aortic
valve implantation registries, severe PH (systolic PAP
>60 mm Hg) is also a powerful predictor of 1-year
mortality (Table 3) (29). Interestingly, PH is revers-
ible, at least partially, in most patients after AVR or
transcatheter aortic valve implantation, which may
lead to a more favorable long-term outcome (28).
Such an improvement seems greater in patients with
higher pre-operative PCWP (27). The frequent retro-
spective design of all of these studies explain the lack
of the precise cause of death being available, and the
mechanisms leading to post-operative fatal events in
patients with PH remain unclear. Nonetheless, a high
rate of atrial ﬁbrillation, stroke, and renal failure have
been post-operatively observed in these patients.
Limited data are available in patients with asymp-
tomatic AS. However, when present, PH may reﬂect
an already advanced disease process (30).
MANAGEMENT OF AS AND PH AT REST. In the recent
European Society of Cardiology (ESC) (31) and Amer-
ican College of Cardiology/American Heart Associa-
tion (32) guidelines, AVR was recommended as a Class
I indication in patients with severe AS and symptoms
at rest or exercise and/or LV dysfunction (LV ejection
fraction <50%). Although peri-operative morbidity
and mortality increase signiﬁcantly in the presence of
PH, this factor is not considered a trigger for AVR.
However, when present, PH is often associated with
symptoms that are frequently underreported or sub-
tle, especially in elderly subjects. The average re-
ported survival of patients with symptomatic AS is
<2 years. Hence, the presence of PH in apparently
asymptomatic patients should raise suspicion about
hidden symptoms and might represent an additional
incentive for early selective surgery; however, further
investigation will be required.
RISK STRATIFICATION IN AS: THE ROLE OF EXERCISE
PH. Exercise stress echocardiography is very useful
in patients with AS (33). The prognostic value of
exercise-induced changes in the mean aortic pressure
gradient has been demonstrated in 2 studies (34,35),
and an increase of >20 mm Hg is a ESC Class IIb
indication for surgery in asymptomatic patients with
preserved LV ejection fraction. Some studies also
showed that assessment of systolic PAP during exer-
cise provides incremental prognostic value beyond
that obtained from the exercise changes in trans-
valvular gradient. Exercise PH (systolic PAP
>60 mm Hg) is more frequent than resting PH (55%vs. 6%, respectively) and is mainly determined by
male sex, resting systolic PAP, and exercise LV pa-
rameters of diastolic burden (i.e., LV end-diastolic
volume, LA area, and e0-wave velocity) (11). In the
study of Lancellotti et al. (11), exercise PH was asso-
ciated with an alarming rate of cardiac death (12%)
and reduced overall cardiac event-free survival in
patients with asymptomatic severe AS. Exercise PH
doubled the risk of cardiac events in these patients
(Figure 5A) and had an incremental prognostic value
beyond AS severity parameters (i.e., peak aortic jet
velocity <4 m/s). Patients with exercise PH require a
closer follow-up to rapidly identify the onset of
symptoms. When peak aortic jet velocity is >4 m/s
and exercise PH is observed, patients might be
referred for elective AVR. Conversely, in the absence
of exercise PH, patients can be followed up safely.
MITRAL STENOSIS
PREVALENCE. MS, when moderate to severe, is
generally associated with a variable degree of PH
(Table 3). The exact prevalence of moderate (14% to
33%) and severe (5.0% to 9.6%) PH varies widely ac-
cording to studies, the spectrum of MS severities, and
symptomatic status (36–38). Derived from cardiac
catheterization (n ¼ 312; various degrees of MS; un-
published data) (Figure 3), 32% of patients had mild
FIGURE 5 Impact of PHT on Outcome in Asymptomatic Patients With VHD
(A) Patients with aortic stenosis and exercise PHT, deﬁned as systolic PAP >60 mm Hg, had a signiﬁcantly reduced cardiac event-free survival. (B) Patients with primary
mitral regurgitation and resting PHT, deﬁned as systolic PAP >50 mm Hg, had a signiﬁcantly reduced symptom-free survival. (C) Patients with primary mitral regur-
gitation and exercise PHT had a signiﬁcantly reduced symptom-free survival. HR ¼ hazard ratio; NS ¼ nonsigniﬁcant; PHT ¼ pulmonary hypertension; other abbreviations
as in Figures 1 and 4. Reproduced with permission from Magne et al. (10) and Lancellotti et al. (30).
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92PH (mean PAP >25 mm Hg), 14% moderate PH (mean
PAP >35 mm Hg), and 9.6% severe PH (mean PAP >45
mm Hg).
IMPACT ON OUTCOME. The natural history of pa-
tients with untreated MS was deﬁned from studies
in the 1960s. Due to the strong association with
symptoms, the presence of PH in patients with MS is
associated with markedly worse outcomes. However,
limited data are available frommodern series. In 2005,
Maoqin et al. (39) reported that patients with MS andvery severe PH (systolic PAP >80 mm Hg) had signif-
icantly higher New York Heart Association (NYHA)
functional class both before and after percutaneous
balloon mitral valvuloplasty. In addition, these pa-
tients displayed a trend for higher cardiovascular
event rate during follow-up. Similarly, from a cohort
of 531 patients referred for percutaneous balloon
mitral valvuloplasty, 15% had severe PH (systolic PAP
>60 mm Hg), and these patients exhibited a signiﬁ-
cantly reduced long-term cardiac event-free survival
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93compared with those with normal systolic PAP (40).
Overall, once symptomatic patients develop severe
PH, their mean survival drops to <3 years (41).
Congestive heart failure, acute pulmonary edema, and
RV heart failure are the predominant causes of death.
EXERCISE SYSTOLIC PAP IN MS. In patients with MS,
exercise is often accompanied by a rise in LA pres-
sure, transmitral mean pressure gradient, and systolic
PAP in response to increased heart rate and ﬂow.
Furthermore, a low atrial compliance may exacerbate
the exercise-induced increase in systolic PAP.
Patients with low atrial compliance and exercise PH
often have reduced ﬂow and as a consequence, the
MS severity may be underestimated (42). In a study
by Brochet et al. (43), asymptomatic patients with MS
who stopped exercise because of dyspnea exhibited a
signiﬁcantly higher and more rapid increase in the
mean transmitral pressure gradient and systolic PAP
at low levels of exercise than did patients without
symptoms. An increase in systolic PAP of $90% in the
early stages of the exercise test (i.e., at an exercise
load of 60 W) was associated with a >2-fold higher
rate of exercise dyspnea or mitral valve intervention
during follow-up. Conversely, peak exercise systolic
PAP, even when >60 mm Hg, did not discriminate
patients with versus without exercise-limiting
symptoms. Hence, the evaluation of the kinetics of
exercise-induced changes in systolic PAP may pro-
vide incremental information to predict symptoms
and prognosis in MS (13).
MANAGEMENT OF PATIENTS WITH MS. Current
European and American guidelines (31,32) recom-
mend percutaneous balloon mitral valvuloplasty or
surgery for all patients with symptomatic signiﬁcant
MS (valve area <1.5 cm2). In contrast, symptomatic
patients with mild MS (mean transmitral pressure
gradient of <5 mm Hg and valve area of >1.5 cm2)
should be followed up on an annual basis but do not
require further evaluation in the initial work-up.
Resting PH has a modest role in the management of
patients with MS. In the European guidelines,
percutaneous balloon mitral valvuloplasty should be
considered (Class IIa) in asymptomatic patients
without unfavorable clinical characteristics and high
risk of hemodynamic decompensation (i.e., systolic
PAP >50 mm Hg at rest). In the American recom-
mendations, it is also preferable to intervene before
the development of very severe PH because those
patients with near systemic pulmonary pressure show
reduced RV function and persistent PH following
percutaneous balloon mitral valvuloplasty or mitral
valve surgery. Percutaneous balloon mitral valvulo-
plasty is also advised for asymptomatic patients withmoderate or severe MS and exercise percutaneous
balloon mitral valvuloplasty >25 mm Hg. Early work
in the percutaneous balloon mitral valvuloplasty era
showed that PAP fell following percutaneous balloon
mitral valvuloplasty, in concert with the reduction
in mitral valve gradient and pulmonary vascular
resistance (44). Return to normal or near normal
levels of systolic PAP is expected in most patients.
Interestingly, after treatment, the baseline endothe-
lin 1 concentration has been shown to be an inde-
pendent predictor of a decrease in PAP following
percutaneous balloon mitral valvuloplasty at 6
months following mitral valve surgery (4). Following
percutaneous balloon mitral valvuloplasty, surveil-
lance is necessary for mitral valve restenosis with the
redevelopment of PH.
AORTIC REGURGITATION
PREVALENCE. In aortic regurgitation (AR), PH has
been less studied. Prior studies have reported a prev-
alence of PH deﬁned as a systolic PAP >40 mm Hg in
27% (45) or >60 mm Hg in 24% (46) of patients with
severe chronic AR (Table 3). In our catheterization-
based study (n ¼ 802; various degrees of AR)
(Figure 4), 23% of patients had mild PH (mean
PAP of >25 mm Hg), 9% moderate PH (mean PAP
of >35 mm Hg), and 4.7% severe PH (mean PAP
of >45 mm Hg).
IMPACT ON OUTCOME AND MANAGEMENT. There
are very few data in the literature regarding the
impact of PH in patients with chronic AR. In the small
series of Naidoo et al. (46), post-operative patients
with PH did not have signiﬁcantly different rates of
post-operative death, complications, or NYHA func-
tional class. In contrast, systolic PAP >40 mm Hg was
associated with reduced survival at 1 and 4 years
following AVR in other series (45). More recently, a
single-center retrospective study of 506 patients with
severe AR demonstrated that severe PH (systolic
PAP >60 mm Hg) was present in approximately 16%
of patients and was associated with LV enlargement
and dysfunction and with ensuing AR. Multivariable
analysis with propensity score adjustment showed an
independent association between AVR and survival in
patients with both severe AR and severe PH during
5 years of follow-up (47). AVR was associated with a
3% operative mortality rate in patients with severe
PH, and systolic PAP dropped to near normal values
in the vast majority of patients following surgery. In
the current guidelines, AVR for AR is not recom-
mended based on the sole presence of PH. However,
in patients with borderline LV dimension values, PH
should dictate a careful search for limited functional
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AVR.
PRIMARY MR
PREVALENCE. In MR, PH has been largely docu-
mented (Table 3, Figure 4). Owing to the relationship
reported between MR grade (48), regurgitant volume
or effective regurgitant oriﬁce area, and systolic PAP
(10,49,50), the rate of PH varies according to MR
severity. In severe MR, moderate/severe PH was
noted in 17%/23% to 32% of patients, with a higher
prevalence according to symptomatic status and the
presence of LV systolic dysfunction (systolic PAP
>50 mm Hg in 64% of NYHA functional class III to IV)
(51). In asymptomatic primary MR, the concomitant
presence of signiﬁcant MR and PH is relatively rare.
The prevalence of PH accounts for approximately 6%
to 30% in asymptomatic patients (48,52,53) and does
not exceed 20% when LV ejection fraction is pre-
served (10,54).
IMPACT ON OUTCOME. In primary MR with pre-
served LV ejection fraction, pre-existing PH is asso-
ciated with post-operative LV systolic dysfunction
(LV ejection fraction <50%) (53). Although the decline
in LV ejection fraction is more pronounced in those
with severe PH (systolic PAP >60 mm Hg), the drop in
LV systolic function also occurs in moderately
elevated systolic PAP (30 to 49 mm Hg). Barbieri et al.
(52) reported a reduced 5-year survival rate (63  5%
vs. 86  2%) and an increase in the incidence of
heart failure during follow-up in patients with PH
compared with those without PH. At 8 years, only
58% of patients with a systolic PAP >50 mm Hg were
alive (48). After adjustment for cofactors, the pres-
ence of PH independently multiplied by 2 the risk of
death or occurrence of heart failure. Despite a sig-
niﬁcant decrease in PAP, without normalization,
mainly in patients with severe and moderate PH (51),
patients with severe MR and PH had signiﬁcantly
reduced post-operative survival compared with those
without PH. Similar results were reported by Le
Tourneau et al. (48), who showed a rate of post-
operative survival approximately divided by 2 at the
8-year follow-up (Table 3) in patients with pre-
operative PH. In addition, the proportion of patients
having persisting symptoms following surgery is
more important among patients with pre-operative
PH. A surgical series found consistent results and
showed a graded relationship between increased
systolic PAP and reduced post-operative survival (51).
Based on these results, the investigators of the Mitral
Regurgitation International Database (52) suggested
that early intervention might be beneﬁcial in patientswith PH, regardless of symptoms or LV functional
status. Such a strategy was further supported by other
data showing that the prognosis of patients with
severe MR and PH is markedly improved when sur-
gery is performed early (<3 months after the index
examination) in the course of the disease (i.e.,
compared with the conservative approach) (52). In
this series, the vast majority of deaths were from
cardiovascular causes and were related to congestive
heart failure.
In asymptomatic patients with preserved LV ejec-
tion fraction, Magne et al. (10) found that patients
with PH had a signiﬁcantly lower symptom-free sur-
vival (Figure 5B) (i.e., only one-third of these patients
remained free of symptoms at the 2-year follow-up).
As in the study of Kusunose et al. (54), this relation-
ship was no longer signiﬁcant after adjustment for
age and sex.
EXERCISE PH IN PRIMARY MR. In opposition to
resting PH, exercise PH is more prevalent in asymp-
tomatic patients with primary MR and no LV
dysfunction/dilation (ejection fraction <60%/end-
systolic diameter <40 to 45 mm). In these patients,
exercise PH has been associated with signiﬁcantly
lower symptom-free survival (at 2 years 75  7% vs.
35  8%; p < 0.0001) (Table 3, Figure 5C). The pres-
ence of exercise PH multiplied by 2.1 the risk of
developing symptoms during follow-up. At the 3-year
follow-up, only 20% of the patients with exercise PH
at baseline remained free of symptoms and at 2 years,
whereas 75% of the patients without exercise PH
remained free of symptoms. These data were recently
conﬁrmed in a comparable cohort of 196 patients (54).
Exercise systolic PAP was an independent predictor
of the need for mitral valve surgery. Compared with
patients without exercise PH/RV dysfunction,
patients with 1 of these 2 exercise conditions had
intermediate outcomes. Conversely, exercise PH
(systolic PAP $54 mm Hg) in conjunction with exer-
cise RV dysfunction identiﬁed patients with worse
outcomes. Pre-operative baseline exercise PH also
negatively impacts post-operative outcome, with a
higher rate of cardiac events (55). Furthermore, pre-
operative exercise PH is associated with signiﬁcantly
reduced post-operative event-free survival, including
a higher rate of late atrial ﬁbrillation and cardiac-
related hospitalization (55).
MANAGEMENT OF PRIMARY MR AND PH. In the
European and American guidelines regarding the
management of asymptomatic patients with severe
primary MR, no LV dysfunction/dilation and resting
PH (systolic PAP >50 mm Hg), mitral valve repair is a
Class IIa indication (Level of Evidence: B or C). Repair
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95can also be considered in high-volume centers in cases
of isolated exercise PH (systolic PAP >60 mm Hg; ESC
Class IIb, Level of Evidence: C) (Table 3). Otherwise,
very close follow-up in a dedicated heart valve clinic
(56) is recommended.
SECONDARY MITRAL REGURGITATION
PREVALENCE. Overall, the prevalence of PH in pa-
tients with LV systolic dysfunction and secondary MR
is approximately 40% (37% moderately elevated sys-
tolic PAP and 22% to 38% severe) (57–59). PH can also
be found in patients with preserved LV ejection
fraction and secondary MR (59). Of note, secondary
MR is a major determinant of elevated systolic PAP in
both conditions (Table 3) (60).
IMPACT ON OUTCOME. In patients with LV dys-
function, PH is associated with an increased risk of
congestive heart failure and mortality (61,62). In a
large cohort of patients undergoing mitral valve sur-
gery (N ¼ 873) for various etiologies of MR, including
functional MR in 31% of cases, Ghoreishi et al. (51)
found that PH was associated with worse post-
operative outcomes (Table 3). In the study of Agri-
cola et al. (63), systolic PAP was also an independent
determinant of heart failure or death.
The recent study by Miller et al. (59) conﬁrmed
these data. The researchers identiﬁed 2 cohorts of
patients with secondary MR with or without PH
(systolic PAP >45 mm Hg) matched for age, sex, LV
ejection fraction, severity of MR, and year of exami-
nation. PH was independently associated with
reduced survival after adjustment for clinical vari-
ables, including symptomatic status, MR severity,
and LV systolic and diastolic functions, carrying an
excess mortality rate of >30% (Table 3).
EXERCISE PH IN SECONDARY MR. Exercise-induced
increase in systolic PAP can occur in patients with
secondary MR regardless of whether the LV systolic
function is preserved or not. It often parallels the
increase in MR severity and LV ﬁlling pressures as
evaluated by E/e0 (64–66). When dynamic MR and
exercise PH are concomitant, worsening heart failure,
worsening pulmonary edema, and increased mor-
tality rate are potential complications. The optimal
cut point for predicting an increase in the number of
future cardiac events was a 21-mm Hg increase in
systolic PAP. During exercise, the abrupt increase in
MR severity, even if mild, may exceed the level of LA
compliance and pulmonary vascular recruitment and
lead to PH. Although initially benign with no sig-
niﬁcant consequences, such a phenomenon, when
repetitive, can progressively lead to LA dilation,
increased LV ﬁlling pressures, atrial ﬁbrillation, RVdysfunction, low-level exercise dyspnea, and ﬁnally
resting symptoms. In addition, this phenomenon is
involved in the pathogenesis of acute pulmonary
edema (67) and is associated with reduced survival,
regardless of the resting severity of MR.
MANAGEMENT AND RISK STRATIFICATION. The
European guidelines recommend surgery as a Class
I indication in patients with severe secondary
MR (effective regurgitant oriﬁce >20 mm2 and/or
regurgitant volume >30 ml) undergoing coronary
artery bypass graft. In the presence of moderate sec-
ondary MR, the indication for valve surgery at the
time of coronary artery bypass grafting is a Class IIa
indication. However, because secondary MR is dy-
namic by nature, exercise stress echocardiography is
highly recommended in patients with moderate MR
(68). In these patients, a large increase in MR associ-
ated with PH and dyspnea on exercise stress echo-
cardiography are further incentives to combined
valve and coronary artery bypass grafting surgeries.
In the absence of planned surgical revascularization,
close follow-up is mandatory, and other mitral valve
treatments may be discussed. Conversely, in patients
with moderate secondary MR and no exercise PH, a
medical strategy should be followed.
Although controversial in terms of outcome beneﬁt,
the goal of surgical treatment is to reduce MR, prevent
its recurrence, and promote LV reverse remodeling.
Restricting annuloplasty may be less effective in
patients with severe mitral valve deformation, with a
higher risk of residual MR after surgery, which can
limit the post-operative improvement in systolic PAP.
In addition, the insertion of a small rigid ring to ach-
ieve a very restrictive annuloplasty may create some
degree of post-operative MS (69), with both resting
and exercise hemodynamic consequences (70), such
as PH. Following restrictive mitral valve annuloplasty
for secondary MR, PH is associated with adverse
cardiac events (71). On the other hand, the risk of
prosthesis-related complications following mitral
valve replacement is not null and should be carefully
assessed pre-operatively. Following mitral valve
replacement, prosthesis-patient mismatch may occur
and may be associated with an increased risk of post-
operative PH (72) and reduced survival (73). Because
secondary MR is mainly a ventricular disease,
surgical strategies solely targeting the mitral valve
may provide suboptimal and inconsistent results. The
randomized controlled trial performed by the Cardio-
thoracic Surgical Trials Network (74) showed no sig-
niﬁcant difference in LV reverse remodeling or
survival at 12 months between patients randomly
assigned to undergo mitral valve repair or mitral valve
replacement for ischemic MR.
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96EMERGING CONCEPTS: BIOMARKERS
Previous studies (75,76) have demonstrated that
plasma B-type natriuretic peptide (BNP) activation
may be a surrogate marker of adverse LA and LV
remodeling. In several studies, BNP levels were
correlated with systolic PAP at rest or during
exercise (76–79). Overall, BNP evaluation may
serve to identify patients who are susceptible to
developing PH.
Pim-1 is a proto-oncogene encoding a serine/
threonine protein kinase that is minimally expressed
in healthy cells but is implicated in cardiac remodel-
ing, along with systemic vascular smooth muscle cell
(SMC) proliferation. Recent studies have demon-
strated that Pim-1 activation in systemic vascular
SMCs enhances nuclear factor of activated T cells
(NFAT) activity in PH (80). NFAT activation is not
restricted to SMCs but is also found in circulating T
cells of patients with PH. Although NFAT activation in
T cells is involved in numerous physiological and
pathological processes, such as inﬂammation, the
activation of NFAT through Pim-1 is speciﬁc to PA
remodeling, suggesting that circulating Pim-1 levels
might represent a good biomarker for PH. In support
of this hypothesis, it was recently reported that
circulating levels of Pim-1 appropriately discrimi-
nated proliferative PH from control subjects and was
an independent predictor of mortality in patients
with PH (81).
RV failure is the major cause of morbidity and
mortality in PH. There are very few studies about the
prevalence and impact of RV dysfunction on out-
comes in patients with VHD. However, a recent study
reported that exercise RV dysfunction is associated
with worse prognosis in these patients (54). The
myocyte enhancer factor 2–microRNA-208 axis
seemed to drive the decompensation of RV function
in pre-capillary PH in recent unpublished data.
Similar mechanisms may be involved in the devel-
opment of RV dysfunction in VHD-related PH, mainly
when MR is present. Preliminary data also implicate
microRNA-126, a pro-angiogenic microRNA, in RV
failure. These ﬁndings open a new window on the
mechanisms that drive RV failure in PH and VHD,
which could be explored in biomarkers (microRNA-
208 and microRNA-126 levels) and therapeutic
research programs.
DISEASE-TARGETED THERAPY
The European guidelines (1) state that there is
currently no speciﬁc therapy for PH related to left
heart disease. Any medical treatment that plays arole in the decrease in LV end-diastolic pressure
may potentially lower PAP, although no evidence
is available in the setting of VHD. The classic
recommended treatment for primary PH targeting
the pulmonary vasculature and RV ejection
impedance was investigated in PH due to left heart
disease, but the results of these studies were not
satisfactory.
Regarding therapeutic management of PH re-
lated to VHD, guidelines recommend (Class I, Level of
Evidence: C) optimizing the treatment of the under-
lying VHD. PH is markedly more prevalent in patients
with severe VHD and in those with surgical indica-
tion. In addition, PH itself is a trigger for surgery in
MR and MS. Consequently, the ﬁrst-line therapeutic
target in these patients is to remove the valvular
burden.
The systolic PAP may decrease following AVR
(82), mitral valve replacement (83), or percutaneous
balloon mitral valvuloplasty. Nevertheless, following
mitral valve replacement, the presence of prosthesis-
patient mismatch precluded normalization of systolic
PAP and was associated with a high rate of post-
operative PH (83), which was an independent deter-
minant of chronic heart failure–related post-operative
hospitalization (72) and mortality (73). Overall,
following VHD interventions, any post-operative
residual hemodynamic alteration limiting reduction
in LA pressure may potentially delay improvement in
PAP and symptoms or even, in some cases, participate
to maintain the presence of PH.
CONCLUSIONS
The presence of PH in left-sided VHD is frequent and
of high prognostic signiﬁcance. The assessment of PH
is crucial in these patients, more particularly in the
absence of overt symptoms because there are impor-
tant implications with regard to risk stratiﬁcation
and management. Nevertheless, owing to relatively
limited data derived from a large cohort of patients
with VHD, the place of PH in current guidelines
remains limited, except in primary MR.
The role of exercise stress echocardiography and
evaluation of exercise PH is gaining interest. Exercise
PH is likely helpful in identifying patients with
advanced risk of rapid and frequent development of
symptoms who may require and beneﬁt from early
intervention. There is no speciﬁc treatment for
patients with PH related to VHD, and therapeutic
management only targets the underlying disease. In
addition, further data are needed to conﬁrm the real
prevalence and impact on outcome of PH in asymp-
tomatic left-sided VHD.
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